pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Neurology · news · pharmadog
← back to Neurology
News · Neurology
173
stories
17h
7 biopharma M&A deals where layoffs followed
biospace
1d
STAT+: Brain organoids, kept alive more than five years, matured like human brains
stat
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
11 companies hiring in New Jersey
biospace
3d
FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
fiercebiotech
3d
How AI-enabled Software as Medical Devices are Reshaping Regulatory Routes and Medicine
biospace
4d
Experts propose safety framework for improving predictability, interpretation of CNS toxicity
raps
6d
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
8d
7 companies hiring in North Carolina now
biospace
10d
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
biopharma dive
10d
Jazz bets on epilepsy again by acquiring Actio for $820M upfront
endpoints
10d
Denali climbs past Avlayah expectations with $3.6M in revenue
biospace
10d
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
fiercebiotech
10d
Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?
biospace
14d
BioVie shares halve on murky Parkinson’s disease readout
biospace
14d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
14d
Takeda approval ushers in new wave of sleep drugs
biopharma dive
14d
BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program
fiercebiotech
15d
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
15d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
15d
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
fda medwatch
17d
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
17d
Supernus, Indivior merge to beef up brain drug portfolio
biopharma dive
17d
Curium strikes up to $8B deal for radiopharma rival Lantheus
fiercebiotech
17d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
17d
Update: Supernus, Indivior to merge and form CNS-focused drugmaker
endpoints
17d
Opinion: I’m a neurologist. I’ve delivered ALS diagnoses. Then I received one myself
stat
20d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
21d
Life after the lead asset: Advancing an early-stage pipeline
biospace
21d
Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance
fiercebiotech
← prev
page 1 of 6
next →
